Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
Add more filters










Publication year range
1.
J Am Heart Assoc ; 9(10): e016223, 2020 05 18.
Article in English | MEDLINE | ID: mdl-32390485

ABSTRACT

Background Patients at increased risk for coronary artery disease and adverse prognosis during heart failure exhibit increased levels of circulating trimethylamine N-oxide (TMAO), a metabolite formed in the metabolism of dietary phosphatidylcholine. We investigated the efficacy of dietary withdrawal of TMAO as well as use of a gut microbe-targeted inhibitor of TMAO production, on cardiac function and structure during heart failure. Methods and Results Male C57BLK/6J mice were fed either control diet, a diet containing TMAO (0.12% wt/wt), a diet containing choline (1% wt/wt), or a diet containing choline (1% wt/wt) plus a microbial choline trimethylamine lyase inhibitor, iodomethylcholine (0.06% wt/wt), starting 3 weeks before transverse aortic constriction. At 6 weeks after transverse aortic constriction, a subset of animals in the TMAO group were switched to a control diet for the remainder of the study. Left ventricular structure and function were monitored at 3-week intervals. Withdrawal of TMAO from the diet attenuated adverse ventricular remodeling and improved cardiac function compared with the TMAO group. Similarly, inhibiting gut microbial conversion of choline to TMAO with a choline trimethylamine lyase inhibitor, iodomethylcholine, improved remodeling and cardiac function compared with the choline-fed group. Conclusions These experimental findings are clinically relevant, and they demonstrate that TMAO levels are modifiable following long-term exposure periods with either dietary withdrawal of TMAO or gut microbial blockade of TMAO generation. Furthermore, these therapeutic strategies to reduce circulating TMAO levels mitigate the negative effects of dietary choline and TMAO in heart failure.


Subject(s)
Bacteria/drug effects , Enzyme Inhibitors/pharmacology , Gastrointestinal Microbiome/drug effects , Heart Failure/drug therapy , Intestines/microbiology , Methylamines/metabolism , Ventricular Function, Left/drug effects , Ventricular Remodeling/drug effects , Animals , Bacteria/enzymology , Bacterial Proteins/antagonists & inhibitors , Bacterial Proteins/metabolism , Choline/metabolism , Disease Models, Animal , Down-Regulation , Fibrosis , Heart Failure/microbiology , Heart Failure/pathology , Heart Failure/physiopathology , Lyases/antagonists & inhibitors , Lyases/metabolism , Male , Mice, Inbred C57BL , Myocardium/pathology
2.
JACC Basic Transl Sci ; 3(6): 796-809, 2018 Dec.
Article in English | MEDLINE | ID: mdl-30623139

ABSTRACT

Cardioprotective effects of H2S have been well documented. However, the lack of evidence supporting the benefits afforded by delayed H2S therapy warrants further investigation. Using a murine model of transverse aortic constriction-induced heart failure, this study showed that delayed H2S therapy protects multiple organs including the heart, kidney, and blood-vessel; reduces oxidative stress; attenuates renal sympathetic and renin-angiotensin-aldosterone system pathological activation; and ultimately improves exercise capacity. These findings provide further insights into H2S-mediated cardiovascular protection and implicate the benefits of using H2S-based therapies clinically for the treatment of heart failure.

3.
Am J Physiol Heart Circ Physiol ; 314(2): H311-H321, 2018 02 01.
Article in English | MEDLINE | ID: mdl-29101177

ABSTRACT

Oxidative stress results in mtDNA damage and contributes to myocardial cell death. mtDNA repair enzymes are crucial for mtDNA repair and cell survival. We investigated a novel, mitochondria-targeted fusion protein (Exscien1-III) containing endonuclease III in myocardial ischemia-reperfusion injury and transverse aortic constriction (TAC)-induced heart failure. Male C57/BL6J mice (10-12 wk) were subjected to 45 min of myocardial ischemia and either 24 h or 4 wk of reperfusion. Exscien1-III (4 mg/kg ip) or vehicle was administered at the time of reperfusion. Male C57/BL6J mice were subjected to TAC, and Exscien1-III (4 mg/kg i.p) or vehicle was administered daily starting at 3 wk post-TAC and continued for 12 wk. Echocardiography was performed to assess left ventricular (LV) structure and function. Exscien1-III reduced myocardial infarct size ( P < 0.01) at 24 h of reperfusion and preserved LV ejection fraction at 4 wk postmyocardial ischemia. Exscien1-III attenuated TAC-induced LV dilation and dysfunction at 6-12 wk post-TAC ( P < 0.05). Exscien1-III reduced ( P < 0.05) cardiac hypertrophy and maladaptive remodeling after TAC. Assessment of cardiac mitochondria showed that Exscien1-III localized to mitochondria and increased mitochondrial antioxidant and reduced apoptotic markers. In conclusion, our results indicate that administration of Exscien1-III provides significant protection against myocardial ischemia and preserves myocardial structure and LV performance in the setting of heart failure. NEW & NOTEWORTHY Oxidative stress-induced mitochondrial DNA damage is a prominent feature in the pathogenesis of cardiovascular diseases. In the present study, we demonstrate the efficacy of a novel, mitochondria-targeted fusion protein that traffics endonuclease III specifically for mitochondrial DNA repair in two well-characterized murine models of cardiac injury and failure.


Subject(s)
Cardiovascular Agents/pharmacology , DNA Damage/drug effects , DNA, Mitochondrial/drug effects , Heart Failure/drug therapy , Hypertrophy, Left Ventricular/drug therapy , Ventricular Dysfunction, Left/drug therapy , Ventricular Function, Left/drug effects , Ventricular Remodeling/drug effects , Animals , Apoptosis/drug effects , Apoptosis Regulatory Proteins/metabolism , DNA, Mitochondrial/genetics , DNA, Mitochondrial/metabolism , Disease Models, Animal , Fibrosis , Heart Failure/metabolism , Heart Failure/pathology , Heart Failure/physiopathology , Hypertrophy, Left Ventricular/metabolism , Hypertrophy, Left Ventricular/pathology , Hypertrophy, Left Ventricular/physiopathology , Male , Mice, Inbred C57BL , Mitochondria, Heart/drug effects , Mitochondria, Heart/metabolism , Mitochondria, Heart/pathology , Myocytes, Cardiac/drug effects , Myocytes, Cardiac/metabolism , Myocytes, Cardiac/pathology , Oxidative Stress/drug effects , Recombinant Fusion Proteins/pharmacology , Signal Transduction/drug effects , Stroke Volume/drug effects , Ventricular Dysfunction, Left/metabolism , Ventricular Dysfunction, Left/pathology , Ventricular Dysfunction, Left/physiopathology
4.
Angew Chem Int Ed Engl ; 56(39): 11749-11753, 2017 09 18.
Article in English | MEDLINE | ID: mdl-28700817

ABSTRACT

A strategy to deliver a well-defined persulfide species in a biological medium is described. Under near physiological conditions, the persulfide prodrug can be activated by an esterase to generate a "hydroxymethyl persulfide" intermediate, which rapidly collapses to form a defined persulfide. Such persulfide prodrugs can be used either as chemical tools to study persulfide chemistry and biology or for future development as H2 S-based therapeutic reagents. Using the persulfide prodrugs developed in this study, the reactivity between S-methyl methanethiosulfonate (MMTS) with persulfide was unambiguously demonstrated. Furthermore, a representative prodrug exhibited potent cardioprotective effects in a murine model of myocardial ischemia-reperfusion (MI/R) injury with a bell shape therapeutic profile.


Subject(s)
Esterases/metabolism , Prodrugs/pharmacokinetics , Sulfides/administration & dosage , Activation, Metabolic , Animals , Cardiotonic Agents/administration & dosage , Cardiotonic Agents/chemistry , Cell Line , Dose-Response Relationship, Drug , Drug Development , Methyl Methanesulfonate/analogs & derivatives , Methyl Methanesulfonate/chemistry , Mice , Myocardial Reperfusion Injury/prevention & control , Prodrugs/administration & dosage , Sulfides/chemistry
5.
J Am Heart Assoc ; 5(7)2016 07 05.
Article in English | MEDLINE | ID: mdl-27381758

ABSTRACT

BACKGROUND: Zofenopril, a sulfhydrylated angiotensin-converting enzyme inhibitor (ACEI), reduces mortality and morbidity in infarcted patients to a greater extent than do other ACEIs. Zofenopril is a unique ACEI that has been shown to increase hydrogen sulfide (H2S) bioavailability and nitric oxide (NO) levels via bradykinin-dependent signaling. Both H2S and NO exert cytoprotective and antioxidant effects. We examined zofenopril effects on H2S and NO bioavailability and cardiac damage in murine and swine models of myocardial ischemia/reperfusion (I/R) injury. METHODS AND RESULTS: Zofenopril (10 mg/kg PO) was administered for 1, 8, and 24 hours to establish optimal dosing in mice. Myocardial and plasma H2S and NO levels were measured along with the levels of H2S and NO enzymes (cystathionine ß-synthase, cystathionine γ-lyase, 3-mercaptopyruvate sulfur transferase, and endothelial nitric oxide synthase). Mice received 8 hours of zofenopril or vehicle pretreatment followed by 45 minutes of ischemia and 24 hours of reperfusion. Pigs received placebo or zofenopril (30 mg/daily orally) 7 days before 75 minutes of ischemia and 48 hours of reperfusion. Zofenopril significantly augmented both plasma and myocardial H2S and NO levels in mice and plasma H2S (sulfane sulfur) in pigs. Cystathionine ß-synthase, cystathionine γ-lyase, 3-mercaptopyruvate sulfur transferase, and total endothelial nitric oxide synthase levels were unaltered, while phospho-endothelial nitric oxide synthase(1177) was significantly increased in mice. Pretreatment with zofenopril significantly reduced myocardial infarct size and cardiac troponin I levels after I/R injury in both mice and swine. Zofenopril also significantly preserved ischemic zone endocardial blood flow at reperfusion in pigs after I/R. CONCLUSIONS: Zofenopril-mediated cardioprotection during I/R is associated with an increase in H2S and NO signaling.


Subject(s)
Antihypertensive Agents/pharmacology , Captopril/analogs & derivatives , Heart/drug effects , Hydrogen Sulfide/metabolism , Myocardial Reperfusion Injury/prevention & control , Myocardium/metabolism , Nitric Oxide/metabolism , Animals , Biological Availability , Blotting, Western , Captopril/pharmacology , Cystathionine beta-Synthase/drug effects , Cystathionine beta-Synthase/genetics , Cystathionine beta-Synthase/metabolism , Cystathionine gamma-Lyase/drug effects , Cystathionine gamma-Lyase/genetics , Cystathionine gamma-Lyase/metabolism , Mice , Myocardial Infarction/pathology , Myocardium/pathology , Nitric Oxide Synthase Type III/drug effects , Nitric Oxide Synthase Type III/genetics , Nitric Oxide Synthase Type III/metabolism , Ramipril/pharmacology , Random Allocation , Regional Blood Flow , Reverse Transcriptase Polymerase Chain Reaction , Sulfurtransferases/drug effects , Sulfurtransferases/genetics , Sulfurtransferases/metabolism , Swine , Swine, Miniature , Troponin I/drug effects , Troponin I/metabolism
6.
J Am Chem Soc ; 138(20): 6336-9, 2016 05 25.
Article in English | MEDLINE | ID: mdl-27172143

ABSTRACT

Hydrogen sulfide (H2S) is a critical signaling molecule that regulates many physiological and/or pathological processes. Modulation of H2S levels could have potential therapeutic value. In this work, we report the rational design, synthesis, and biological evaluation of a class of phosphonamidothioate-based H2S-releasing agents (i.e., H2S donors). A novel pH-dependent intramolecular cyclization was employed to promote H2S release from the donors. These water-soluble compounds showed slow, controllable, and pH-sensitive production of H2S in aqueous solutions. The donors also showed significant cytoprotective effects in cellular models of oxidative damage. Most importantly, the donors were found to exhibit potent cardioprotective effects in an in vivo murine model of myocardial ischemia-reperfusion (MI/R) injury through a H2S-related mechanism.


Subject(s)
Disease Models, Animal , Hydrogen Sulfide/metabolism , Myocardial Reperfusion Injury/metabolism , Animals , Hydrogen-Ion Concentration , Mice
7.
J Nutr ; 146(2): 403S-409S, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26764335

ABSTRACT

For centuries, garlic has been shown to exert substantial medicinal effects and is considered to be one of the best disease-preventative foods. Diet is important in the maintenance of health and prevention of many diseases including cardiovascular disease (CVD). Preclinical and clinical evidence has shown that garlic reduces risks associated with CVD by lowering cholesterol, inhibiting platelet aggregation, and lowering blood pressure. In recent years, emerging evidence has shown that hydrogen sulfide (H2S) has cardioprotective and cytoprotective properties. The active metabolite in garlic, allicin, is readily degraded into organic diallyl polysulfides that are potent H2S donors in the presence of thiols. Preclinical studies have shown that enhancement of endogenous H2S has an impact on vascular reactivity. In CVD models, the administration of H2S prevents myocardial injury and dysfunction. It is hypothesized that these beneficial effects of garlic may be mediated by H2S-dependent mechanisms. This review evaluates the current knowledge concerning the cardioprotective effects of garlic-derived diallyl polysulfides.


Subject(s)
Garlic/chemistry , Heart/drug effects , Hydrogen Sulfide/therapeutic use , Myocardium , Phytotherapy , Plant Extracts/therapeutic use , Sulfinic Acids/therapeutic use , Cardiovascular Agents/pharmacology , Cardiovascular Agents/therapeutic use , Disulfides , Humans , Hydrogen Sulfide/metabolism , Hydrogen Sulfide/pharmacology , Plant Extracts/pharmacology , Sulfides/pharmacology , Sulfides/therapeutic use , Sulfinic Acids/pharmacology
8.
Circ Heart Fail ; 9(1): e002314, 2016 Jan.
Article in English | MEDLINE | ID: mdl-26699388

ABSTRACT

BACKGROUND: Trimethylamine N-oxide (TMAO), a gut microbe-dependent metabolite of dietary choline and other trimethylamine-containing nutrients, is both elevated in the circulation of patients having heart failure and heralds worse overall prognosis. In animal studies, dietary choline or TMAO significantly accelerates atherosclerotic lesion development in ApoE-deficient mice, and reduction in TMAO levels inhibits atherosclerosis development in the low-density lipoprotein receptor knockout mouse. METHODS AND RESULTS: C57BL6/J mice were fed either a control diet, a diet containing choline (1.2%) or a diet containing TMAO (0.12%) starting 3 weeks before surgical transverse aortic constriction. Mice were studied for 12 weeks after transverse aortic constriction. Cardiac function and left ventricular structure were monitored at 3-week intervals using echocardiography. Twelve weeks post transverse aortic constriction, myocardial tissues were collected to evaluate cardiac and vascular fibrosis, and blood samples were evaluated for cardiac brain natriuretic peptide, choline, and TMAO levels. Pulmonary edema, cardiac enlargement, and left ventricular ejection fraction were significantly (P<0.05, each) worse in mice fed either TMAO- or choline-supplemented diets when compared with the control diet. In addition, myocardial fibrosis was also significantly greater (P<0.01, each) in the TMAO and choline groups relative to controls. CONCLUSIONS: Heart failure severity is significantly enhanced in mice fed diets supplemented with either choline or the gut microbe-dependent metabolite TMAO. The present results suggest that additional studies are warranted examining whether gut microbiota and the dietary choline → TMAO pathway contribute to increased heart failure susceptibility.


Subject(s)
Bacteria/metabolism , Choline/toxicity , Diet/adverse effects , Heart Failure/chemically induced , Intestines/microbiology , Methylamines/toxicity , Animals , Cardiomegaly/blood , Cardiomegaly/chemically induced , Cardiomegaly/pathology , Choline/metabolism , Disease Models, Animal , Disease Progression , Fibrosis , Heart Failure/blood , Heart Failure/pathology , Heart Failure/physiopathology , Male , Methylamines/blood , Mice, Inbred C57BL , Myocardium/metabolism , Myocardium/pathology , Pulmonary Edema/blood , Pulmonary Edema/chemically induced , Risk Factors , Severity of Illness Index , Stroke Volume , Time Factors , Ventricular Dysfunction, Left/blood , Ventricular Dysfunction, Left/chemically induced , Ventricular Dysfunction, Left/physiopathology , Ventricular Function, Left
9.
J Neurosci ; 33(10): 4605-13, 2013 Mar 06.
Article in English | MEDLINE | ID: mdl-23467376

ABSTRACT

The endogenous circadian clock is a principal factor modulating memory across species. Determining the processes through which the circadian clock modulates memory formation is a key issue in understanding and identifying mechanisms to improve memory. We used the marine mollusk Aplysia californica to investigate circadian modulation of intermediate-term memory (ITM) and the mechanisms through which the circadian clock phase specifically suppresses memory using the operant learning paradigm, learning that food is inedible. We found that ITM, a temporally and mechanistically distinct form of memory, is rhythmically expressed under light-dark and constant conditions when induced by either massed or spaced training. Strong circadian regulation of ITM occurs with memory exhibited only by animals trained during the early subjective day; no apparent memory is expressed when training occurs during the late subjective day or night. Given the necessity of multiple persistent kinase cascades for ITM, we investigated whether protein phosphatase activity affected circadian modulation. Inhibition of protein phosphatases 1 and 2A blocked ITM when animals were trained during the early (subjective) day while resulting in phase-specific memory rescue when animals were trained late in the subjective day and early night. In contrast, inhibition of calcineurin did not block ITM when animals were trained during the early day and permitted ITM when animals were trained during the late subjective day, early evening, and throughout the night. These results demonstrate that levels of protein phosphatase activity are critical regulators of ITM and one mechanism through which the circadian clock regulates memory formation.


Subject(s)
Association Learning/physiology , Circadian Rhythm/physiology , Memory/physiology , Phosphoprotein Phosphatases/metabolism , Analysis of Variance , Animals , Aplysia , Association Learning/drug effects , Calcineurin/metabolism , Circadian Rhythm/drug effects , Enzyme Inhibitors/pharmacology , Light , Memory/drug effects , NG-Nitroarginine Methyl Ester/pharmacology , Reaction Time/drug effects , Reaction Time/physiology , Space Perception/drug effects , Space Perception/physiology , Tacrolimus/pharmacology , Time Factors
10.
J Neurosci ; 32(13): 4581-91, 2012 Mar 28.
Article in English | MEDLINE | ID: mdl-22457504

ABSTRACT

The Aplysia feeding system with its high degree of plasticity and well characterized neuronal circuitry is well suited for investigations of memory formation. We used an operant paradigm, learning that food is inedible (LFI), to investigate the signaling pathways underlying intermediate-term memory (ITM) in Aplysia. During a single massed training session, the animal associates a specific seaweed with the failure to swallow, generating short-term (30 min) and long-term (24 h) memory. We investigated whether the same training protocol induced the formation of ITM. We found that massed LFI training resulted in temporally distinct protein synthesis-dependent memory evident 4-6 h after training. Through in vivo experiments, we determined that the formation of ITM required protein kinase A, protein kinase C, and MAPK. Moreover, the maintenance of ITM required PKA, PKM Apl III, and MAPK because inhibition of any of these kinases after training or before testing blocked the expression of memory. In contrast, additional experiments determined that the maintenance of long-term memory appeared independent of PKM Apl III. Using Western blotting, we found that sustained MAPK phosphorylation was dependent upon protein synthesis, but not PKA or PKC activity. Thus, massed training-induced intermediate-term operant memory requires protein synthesis as well as persistent or sustained kinase signaling for PKA, PKC, and MAPK. While short-, intermediate-, and long-term memory are induced by the same training protocol, considerable differences exist in both the combination and timing of signaling cascades that induce the formation and maintenance of these temporally distinct memories.


Subject(s)
Conditioning, Operant/physiology , Cyclic AMP-Dependent Protein Kinases/physiology , Memory/physiology , Mitogen-Activated Protein Kinases/physiology , Protein Biosynthesis/physiology , Protein Kinase C/physiology , Signal Transduction/physiology , Animals , Aplysia , Conditioning, Operant/drug effects , Cyclic AMP-Dependent Protein Kinases/antagonists & inhibitors , Cyclic AMP-Dependent Protein Kinases/biosynthesis , Memory/drug effects , Mitogen-Activated Protein Kinases/antagonists & inhibitors , Mitogen-Activated Protein Kinases/biosynthesis , Protein Biosynthesis/drug effects , Protein Kinase C/antagonists & inhibitors , Protein Kinase C/biosynthesis , Protein Synthesis Inhibitors/pharmacology , Signal Transduction/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...